Your browser doesn't support javascript.
loading
Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial.
Wade, Julia; Donovan, Jenny; Lane, Athene; Davis, Michael; Walsh, Eleanor; Neal, David; Turner, Emma; Martin, Richard; Metcalfe, Chris; Peters, Tim; Hamdy, Freddie; Kockelbergh, Roger; Catto, James; Paul, Alan; Holding, Peter; Rosario, Derek; Kynaston, Howard; Rowe, Edward; Hughes, Owen; Bollina, Prasad; Gillatt, David; Doherty, Alan; Gnanapragasam, Vincent J; Paez, Edgar.
Afiliação
  • Wade J; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK julia.wade@bristol.ac.uk.
  • Donovan J; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Lane A; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Davis M; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Walsh E; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Neal D; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Turner E; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Martin R; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Metcalfe C; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Peters T; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Hamdy F; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Kockelbergh R; Department of Urology, University Hospitals of Leicester NHS Trust, Leicester, UK.
  • Catto J; Department of Oncology and Metabolism, University of Sheffield Medical School, Sheffield, UK.
  • Paul A; Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Holding P; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Rosario D; Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
  • Kynaston H; School of Medicine, Cardiff University, Cardiff, UK.
  • Rowe E; Department of Urology, North Bristol NHS Trust, Bristol, UK.
  • Hughes O; Department of Urology, Cardiff and Vale University Health Board, Cardiff, UK.
  • Bollina P; Department of Urology, NHS Lothian, Edinburgh, UK.
  • Gillatt D; Faculty of Medicine, Health and Human Science, Macquarie University, Sydney, New South Wales, Australia.
  • Doherty A; Department of Urology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
  • Gnanapragasam VJ; Department of Surgery, University of Cambridge, Cambridge, UK.
  • Paez E; Department of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
BMJ Open ; 10(9): e036024, 2020 09 09.
Article em En | MEDLINE | ID: mdl-32907896
ABSTRACT

OBJECTIVES:

Active surveillance (AS) enables men with low risk, localised prostate cancer (PCa) to avoid radical treatment unless progression occurs; lack of reliable AS protocols to determine progression leaves uncertainties for men and clinicians. This study investigated men's strategies for coping with the uncertainties of active monitoring (AM, a surveillance strategy within the Prostate testing for cancer and Treatment, ProtecT trial) over the longer term and implications for optimising supportive care.

DESIGN:

Longitudinal serial in-depth qualitative interviews every 2-3 years for a median 7 (range 6-14) years following diagnosis.

SETTING:

Four centres within the UK Protect trial.

PARTICIPANTS:

Purposive sample of 20 men with localised PCa median age at diagnosis 64 years (range 52-68); 15 (75%) had low-risk PCa; 12 randomly allocated to, 8 choosing AM. Eleven men continued with AM throughout the study period (median 7 years). Nine received radical treatment after a median 4 years (range 0.8-13.8 years). INTERVENTION AM 3-monthly serum prostate-specific antigen (PSA)-level assessment (year 1), 6-12 monthly thereafter; increase in PSA ≥50% during previous 12 months or patient/clinician concern triggered review. MAIN

OUTCOMES:

Thematic analysis of 73 interviews identified strategies to accommodate uncertainty and anxiety of living with untreated cancer; implications for patient care.

RESULTS:

Men sought clarity, control or reassurance, with contextual factors mediating individual responses. Trust in the clinical team was critical for men in balancing anxiety and facilitating successful management change/continued monitoring. Only men from ProtecT were included; men outside ProtecT may have different experiences.

CONCLUSION:

Men looked to clinicians for clarity, control and reassurance. Where provided, men felt comfortable continuing AM or having radical treatments when indicated. Clinicians build patient trust by clearly describing uncertainties, allowing patients control wherever possible and being aware of how context influences individual responses. Insights indicate need for supportive services to build trust and patient engagement over the long term. TRIAL REGISTRATION NUMBER ISRCTN20141297; Pre-results.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Conduta Expectante Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Conduta Expectante Tipo de estudo: Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies / Screening_studies Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article